PMID- 3855265
OWN - NLM
STAT- MEDLINE
DCOM- 19850201
LR  - 20190619
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 55
IP  - 1
DP  - 1985 Jan 1
TI  - Acute promyelocytic leukemia in 57 previously untreated patients.
PG  - 18-25
AB  - Fifty-seven patients in initial phase of acute promyelocytic leukemia (APL) were 
      treated in the same department with heparin infusion, platelet transfusions, and 
      two related induction regimens both including cytosine arabinoside and 
      daunorubicin. Clinical and biological findings at presentation were studied. The 
      complete remission (CR) rate was 53%. Twenty-seven patients (47%) died during the 
      initial course of the disease, either before day 5 (early death [ED], n = 7) or 
      after day 5 (death in aplasia [DA], n = 20). Most ED was due to intracerebral 
      hemorrhage (6/7), especially when large hemorrhages had been seen on fundus oculi 
      examination. Most DA was due to multivisceral failure (9/20). No correlation was 
      found between initial disseminated intravascular coagulation (DIC) and death. 
      However, the worsening of coagulation parameters during induction therapy, with 
      or without initial DIC, significantly increased the occurrence of renal and 
      respiratory failure which were particularly frequent during the first month. The 
      median duration of survival was short (3.5 months) and the median duration of CR 
      (11 months) was similar to that of other acute myeloid leukemias treated with the 
      same regimens. The possible causes of the high mortality observed during the 
      initial courses of APL and the possible benefit of a more graduate induction 
      chemotherapy are discussed.
FAU - Cordonnier, C
AU  - Cordonnier C
FAU - Vernant, J P
AU  - Vernant JP
FAU - Brun, B
AU  - Brun B
FAU - Heilmann, M G
AU  - Heilmann MG
FAU - Kuentz, M
AU  - Kuentz M
FAU - Bierling, P
AU  - Bierling P
FAU - Farcet, J P
AU  - Farcet JP
FAU - Rodet, M
AU  - Rodet M
FAU - Duedari, N
AU  - Duedari N
FAU - Imbert, M
AU  - Imbert M
AU  - et al.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 04079A1RDZ (Cytarabine)
RN  - 9005-49-6 (Heparin)
RN  - ZS7284E0ZP (Daunorubicin)
SB  - IM
MH  - Acute Kidney Injury/complications
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Blood Transfusion
MH  - Cytarabine/therapeutic use
MH  - Daunorubicin/therapeutic use
MH  - Disseminated Intravascular Coagulation/complications/prevention & control
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Leukemia, Myeloid, Acute/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Transfusion
MH  - Prognosis
MH  - Respiratory Insufficiency/complications
MH  - Time Factors
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1002/1097-0142(19850101)55:1<18::aid-cncr2820550104>3.0.co;2-b [doi]
PST - ppublish
SO  - Cancer. 1985 Jan 1;55(1):18-25. doi: 
      10.1002/1097-0142(19850101)55:1<18::aid-cncr2820550104>3.0.co;2-b.